Alpian, a company incubated by REYL Intesa Sanpaolo, applied for a full banking licence from the SwissFinancial Market Supervisory Authority (FINMA). After a rigorous process, Alpian has become the first licensed digital private bank in
Tags :Schellenberg Wittmer
Kinarus, a privately owned clinical-stage biopharmaceutical company active in the development of novel treatments for patients suffering from serious viral, respiratory and ophthalmic diseases, signed a Transaction Agreement with SIX-listed Perfect Holding regarding Perfect Holding’
Francotyp-Postalia, a stock-listed international active group of companies which provides digital business solutions, mailing, shipping & office solutions and mail services, has acquired all shares in the operating companies of Azolver Group. Azolver Group focuses
Schellenberg Wittmer advised majority shareholder Helvetia, a Swiss insurance group, on its acquisition of a minority stake in MoneyPark, specialist for mortgages and real estate, from TX Group media company. With this acquisition,
Arsenal Capital Partners, a global private equity firm focusing on franchises in the healthcare and industrial sectors, has completes its acquisition of ATP Group from Bregal Unternehmerkapital. Swiss headquartered ATP Group is a manufacturer of
Schellenberg Wittmer advised Credit Suisse on its private banking client referral agreement with Barclays as part of the plan to exit nine wealth management markets primarily in Sub-Saharan Area, excluding South Africa, as announced in
Schellenberg Wittmer has appointed Jean-Frédéric Maraia (pictured) as the new head of the firm’s taxation practice in Geneva. Jean-Frédéric, a leading practitioner and a lecturer at the University of Geneva,
On 27 January 2022, Liechtensteinische Landesbank (LLB), 74.9%-majority shareholder of Bank Linth LLB, has published the pre-announcement for a public tender offer to acquire all of the outstanding shares of Bank Linth. LLB will offer Bank Linth
Schellenberg Wittmer advised Santhera Pharmaceuticals regarding an exclusive license agreement for the Greater China Region with Sperogenix Therapeutics, a China-based company specialising in orphan diseases. Under this agreement, Sperogenix will in-license the drug candidate Vamorolone
Schellenberg Wittmer advises Julius Baer Group on its sale of Wergen & Partner Vermögensverwaltungs, a member of the Julius Baer Group, to the management of Wergen & Partner Vermögensverwaltungs. The parties have signed
